Guidelines for the treatment of women with an abnormal smear;Richtlijnen voor de bechandeling van vrouwen met een abnormaal uitstrijkje

Tijdschrift voor Geneeskunde

Volumn 61, Issue 2, 2005, Pages 108-118

  Tjalma, W ^a,b   Crijns, P ^a,c   De Sutter, P ^a,d   Ide, P ^a,e   Orye, G ^a,f   Poppe, W ^a,g   Verguts, J ^a,b   Watty, K ^a,g   Weyers, S ^a,h   Wuyts, K ^a,i  

^a Vlaamse Vereniging V Obstet/G   (Belgium)

^b Stedelijk Ziekenhuis Roeselare   (Belgium)

^c KLINA Brasschaat   (Belgium)

^d AZ VUB   (Belgium)

^e Salvator Hospital   (Belgium)

^f VIRGA JESSE HOSPITAL   (Belgium)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ Heilig Hart Ziekenhuis   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SCREENING; EVALUATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; PRACTICE GUIDELINE; REVIEW; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY;

EID: 19944431333     PISSN: 0371683X     EISSN: None     Source Type: Journal    
DOI: 10.2143/tvg.61.2.5002078     Document Type: Review

References (92)

1. National Cancer Institute Workshop. The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnoses JAMA 1989; 262: 931-934.
2. The 1991 Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda Workshop. JAMA 1992; 267: 1892.
3. WRIGHT TC Jr, Cox JT, MASSAD LS, TWIGGS LB WILKINSON EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. ASCCP-Sponsored Consensus Conference. JAMA 2002; 257: 2120-2129.
4. SOLOMON D, DAVEY D, KURMAN R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 257: 2114-2119.
5. WRIGHT TC Jr, LORINCZ A, FERRIS DG, et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smears. Am J Obstet Gynecol 1998; 178: 962-966.
6. SOLOMON D, SCHIFFMAN M, TARRONE R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. J Nat Cancer Inst 2001; 93: 293-299.
7. SLAWSON, DC, BENNETT JH, SIMON LJ, HERMAN JM Should all women with cervical atypia be referred for colposcopy: a HARNET study. Harrisburgh Area Research Network. J Fam Pract 1994; 38: 387-392.
8. KOBELIN MH, KOBELIN CG, BURKE L, LAVIN P NILOFF JM, KIM YB. Incidence and predictors of cervical dysplasia in patients with minimally abnormal. Papanicolaou smears. Obstet Gynecol 1998; 92: 356-359.
9. ESKRIDGE C, BEGNEAUD WP, LANDWEHR C: Cervicography combined with repeat Papanicolaou test as triage for low-grade cytologic abnormalities. Obstet Gynecol. 1998; 92: 351-355.
10. CRUM CR GENEST DR, KRANE JF, et al. Subclassifying atypical squamous cells in Thin-Prep cervical cytology correlates with detection of high-risk human papillomavirus DNA. Am J Clin Pathol 1999; 112: 384-390.
11. SCHOOLLAND M, STERRETT GF, KNOWLES SA MITCHELL KM, KURINCZUK JJ. The "Inconclusive-possible high grade epithelial abnormality" category in Papanicolaou smear reporting. Cancer 1998; 84: 208-217.
12. MALIK SN, WILKINSON EJ, DREW PA, BENNETT BB, HARDT NS. Do qualifiers of ASCUS distinguish between low- and high-risk patients? Acta Cytol 1999; 43: 376-380.
13. SHERMAN ME, SOLOMON D, SCHIFFMAN M. Qualification of ASCUS: a comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS LSIL Triage Study (ALTS). Am J Clin Pathol 2001; 116: 386-394.
14. QUDDUS MR, SUNG CJ, STEINHOFF MM, LAUCHLAN SC, SINGER DB, HUTCHINSON ML. Atypical squamous metaplastic cells. Cancer 2001; 93: 16-22.
15. JONES BA, NOVIS DA. Follow-up of abnormal gynecologic cytology: a college of American pathologists Q-probes study of 16 132 cases from 306 laboratories. Arch Pathol Lab Med 2000; 124: 665-671.
16. LONKY NM, SADEGHI M, TSADIK GW, PETITTI D. The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytologic results. Am J Obstet Gynecol 1999; 181: 560-566.
17. American College of Obstetricians and Gynecologists. Cervical Cytology: Evaluation and Management of Abnormalities. Washington, DC: American College of Obestetricians and Gynecologists; 1993: 1-7. ACOG Technical Bulletin 198.
18. SHERMAN ME, TABBARA SO, SCOTT DR, et al. "ASCUS, rule out HSIL": cytologic features, histologic correlates and human papillomavirus detection. Mod Pathol 1999; 12: 335-343.
19. ROBB JA. The "ASCUS" swamp. Diagn Cytopath 1994; 11: 319-320.
20. SHERMAN ME, SCHIFFMAN MH, LORINCZ AT, et al. Toward objective quality assurance in cervical cytopathology. Am J Clin Pathol 1994; 102: 182-87.
21. STOLER MH, SCHIFFMAN M. Interobserver reproducibility of cervical cytologic and histologic interpretations. JAMA 2001; 285: 1500-1505.
22. MANOS MM, KINNEY WK, HURLEY LB, et al. Identifying women with cervical neoplasia. JAMA 1999; 281: 1605-1610.
23. SUN XW, KUHN L, ELLERBROCK TV, CHIASSION MA, WRIGHT TC. Human papillomavirus infection in HIV-seropositive women. N Engl J Med 1997; 337: 1343-1349.
24. BERGERON C, JEANNEL D, PROVEDA J, CASSONNET P, ORTH G. Human papillomavirus testing in women with mild cytologic atypia. Obstet Gynecol 2000; 95: 821-827.
25. FERRIS CT, WRIGHT TC Jr, LITAKERS MS, et al. Comparison of two tests for detecting carcinogenic HPV in women with Papanicolaou smear reports of ASCUS and LSIL. J Fam Pract 1998; 46: 136-141.
26. LIN CT, TSENG CJ, LAI CH, HSUEH S, HUANG HJ, LAW KS. High-risk HPV DNA detection by Hybrid Capture II. J Reprod Med 2000; 45: 345-350.
27. SHLAY JC, DUNN T, BYERS T, BARON AE, DOUGLAS JM Jr. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears. Obstet Gynecol 2000; 96: 410-416.
28. MITCHELL MF, SCHOTTENFELD D, TORTOLERO-LUNA G, CANTOR SB, RICHARDS-KORTUM R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 91: 626-631.
29. SHERMAN ME, SCHIFFMAN M, COX JT, GROUP TA. Effects of age and human papilloma viral load on colposcopy triage. J Natl Cancer Inst 2002; 94: 102-107.
30. WRIGHT TC, MASCARELLI RD, DOLE P, ELLERBROCK TV, CHIASSON MA, VANDEVANTER N. Clinical significance of mild cytologic atypia on Papanicolaou smears from women infected with human immunodeficiency virus. Obstet Gynecol 1996; 87: 515-519.
31. KEATING JT, WANG HH. Significance of a diagnosis of atypical squamous cells of undetermined significance for Papanicolaou smears in perimenopausal and post-menopausal women. Cancer 2001; 93: 100-105.
32. FLYNN K, RIMM DL. Diagnosis of "ASCUS" in women over age 50 is less likely to be associated with dysplasia. Diagn Cytopathol 2001; 24: 132-136.
33. PARK TJ, RICHART RM, SUN X-W, et al. Association between HPV type and clonal status of cervical squamous intraepithelial lesions (SIL). J Natl Cancer Inst 1996; 88: 355-358.
34. WRIGHT TC, KURMAN RJ. A critical review of the morphologic classification systems of preinvasive lesions of the cervix: the scientific basis for shifting the paradigm. Papillomavirus Rep 1994; 5: 175-182.
35. EINSTEIN MH, BURK RD. Persistent human papillomaviral infection: definitions and clinical implications. Papillomavirus Rep 2001; 12: 119-123.
36. ZUR HAUSEN H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92: 690-698.
37. TAKEZAWA K. BENNETT BB, WILKINSON EJ, DREW PA, HARDT NS. Squamous intraepithelial lesions of the cervix in a high-risk population. J Lower Gen Tract Dis 1998; 2: 136-140.
38. FERRIS DG, WRIGHT TC Jr, LITAKER MS, et al. Triage of women with ASCUS and LSIL on Pap smear reports. J Fam Pract 1998; 46: 125-134.
39. ROBERTSON JH, WOODEND B, ELLIOT H. Cytological changes preceding cervical cancer. J Clin Pathol 1994; 47: 278-279.
40. ROBERTSON JH, WOODEND BE, CROZIER EH, HUTCHINSON J. Risk of cervical cancer associated with mild dyskaryosis. BMJ 1988; 297: 18-21.
41. KIRBY AJ, SPIEGELHALTER DJ, DAY NE, et al. Conservative treatment of mild/moderate cervical dyskaryosis: long-term outcome. Lancet 1992; 339: 828-831.
42. Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions. J Natl Cancer Inst 2000; 92: 397-402.
43. BIGRIGG MA, CODLING BW, PEARSON P, READ MD, SWINGLER GR. Colposcopic diagnosis and treatment of cervical dysplasia at a single clinic visit. Lancet 1990; 336: 22-231.
44. LUESLEY DM, CULLIMORE J, REDMAN CW, et al. Loop diathermy excision of the cervical transformation zone in patients with abnormal cervical smears. BMJ 1990; 300: 1690-1693.
45. NAIK R, ABANG-MOHAMMED K, TJALMA WA, et al. The feasibility of a one-stop colposcopy clinic in the management of women with low grade smear abnormalities: a prospective study Eur J Obstet Gynecol Reprod Biol 2001; 98: 205-208.
46. HOWELLS RE, O'MAHONY J, TUCKER H, MILLINSHIP J, JONES PW, REDMAN CW. How can the incidence of negative specimen resulting form large loop excision of the cervical transformation zone (LLETZ) be reduced? BJOG 2000; 107: 1075-1082.
47. SPITZER M, CHERNYS AE, SHIFRIN A, RYSKIN M. Indications for cone biopsy: pathologic correlation. Am J Obstet Gynecol 1998; 178: 74-79.
48. JONES BA, DAVEY DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000; 124: 672-681.
49. KINNEY WK, MANOS MM, HURLEY LB, RANSLEY JE. Where's the high-grade cervical neoplasia? Obstet Gynecol 1998; 91: 973-976.
50. MASSAD LS, COLLINS YC, MEYER PM. Biopsy correlates of abnormal cervical cytology classified using the Bethesda system. Gynecol Oncol 2001; 82: 516-522.
51. KURMAN RJ, HENSON DE, HERBST AL, NOLLER KL, SCHIFFMAN MH. Interim guidelines for management of abnormal cervical cytology. JAMA 1994; 271: 1866-1869.
52. JONES BA, NOVIS DA. Cervical biopsy-cytology correlation: a College of American Pathologists Q-Probes study of 22 439 correlations in 348 laboratories. Arch Pathol Lab Med 1996; 120: 523-531.
53. BROWN FM, FAQUIN WC, SUN D CRUM CP, CIBAS ES. LSIL biopsies after HSIL smears. Am J Clin Pathol 1999; 122: 765-768.
54. CHAPPATTE OA, BYRNE DL, RAJU KS, NAYAGAM M, KENNEY A. Histological differences between colposcopic-directed biopsy and loop excision of the transformation zone (LETZ). Gynecol Oncol 1991; 43: 46-50.
55. MILNE DS, WADEHRA V, MENNIM D, WAGSTAFF TI. A prospective follow up study of women with colposcopically unconfirmed positive cervical smears. Br J Obstet Gynaecol 1999; 106: 38-41.
56. GRENKO RT, ABENDROTH CS, FRAUENHOFFER EE, RUGGIERO FM, ZAINO RJ. Variance in the interpretation of cervical biopsy specimens obtained for atypical squamous cells of undetermined significance. Am J Clin Pathol 1996; 114: 735-740.
57. JOSTE NE, RUSHING L, GRANADOS R, et al. Bethesda classification of cervicovaginal smears: reproductibility and viral correlates. Hum Pathol 1996; 27: 581-585.
58. BIGRIGG A, HAFFENDEN DK, SHEEHAN AL, CODLING BW, READ MD. Efficacy and safety of large-loop excision of the transformation zone. Lancet 1994; 343: 32-34.
59. DENNY LA, SOETERS R, DEHAECK K, BLOCK B. Does colposcopically directed punch biopsy reduce the incidence of negative LLETZ? Br J Obstet Gynaecol 1995; 102: 545-548.
60. HOLSCHNEIDER CH, FELIX JC, SATMARY W, JOHNSON MT, SANDWEISS LM, MONTZ FJ. A single-visit cervical carcinoma prevention program offered at an inner city church: A pilot project. Cancer 1999; 86: 2659-2667.
61. SANTOS C, GALDOS R, ALVARES J, et al. One-session management of cervical intraepithelial neoplasia: a solution for developing countries. Gynecol Oncol 1996; 61: 11-15.
62. BENEDET JL, SELKE PA, NICKERSON K. Colposcopic evaluation of abnormal Papanicolaou smears in pregnancy. Am J Obstet Gynecol 1987; 157: 932-937.
63. ECONOMOS K, PEREZ VERIDIANO N, DELKE I, COLLADO ML, TANCER ML. Abnormal cervical cytology in pregnancy: a 17-year experience. Obstet Gynecol 1993; 81: 915-918.
64. WOODROW N, PERMEZEL M, BUTTERFIELD L, ROME R, TAN J, QUINN M. Abnormal cervical cytology in pregnancy. Aust NZJ Obstet Gynaecol 1998; 38: 161-165.
65. GONDOS B, KING EB. Significance of endometrial cells in cervicovaginal smears. Ann Clin Lab Sci 1977; 7: 486-490.
66. MONTZ FJ. Significance of "normal" endometrial cells in cervical cytology form asymptomatic postmenopausal women receiving hormone replacement therapy. Gynecol Oncol 2001; 81: 33-39.
67. RÖNNET BM, MANOS MM, RANSLEY JE, et al. Atypical glandular cells of undetermined significance (AGUS). Hum Pathol 1999; 30: 816-825.
68. KENNEDY AW, SALMIERE SS, WIRTH SL, BISCOTTI CV, TUASON LJ, TRAVARCA MJ. Results of the clinical evaluation of atypical glandular cells of undetermined significance (AGCUS) detected on cervical cytology screening. Gynecol Oncol 1996; 63: 14-18.
69. VALDINI A, VACCARO C, PECHINSKY G, ABERNATHY V. Incidence and evaluation of an AGUS Papanicolaou smear in primary care. J Am Board Fam Pract 2001; 14: 172-177.
70. DUSKA LR, FLYNN CF, CHEN A, WHALL-STROJWAS D, GOODMAN A. Clinical evaluation of atypical glandular cells of undetermined significance on cervical cytology. Obstet Gynecol 1998; 91: 278-282.
71. TAYLOR RR, GUERRIERI JP, NASH JD, HENRY MR, O'CONNOR DM. Atypical cervical cytology: colposcopic follow-up using the Bethesda System. J Reprod Med 1993; 38: 443-447.
72. GOFF BA, ATANASOFF P, BROWN E, MUNTZ HG, BELL DA, RICE LW. Endocervical glandular atypia in Papanicolaou smears. Obstet Gynecol 1992; 79: 101-104.
73. ZWEIZIG S, NOLLER K, REALE F, COLLIS S, RESSEGUIE L. Neoplasia associated with atypical glandular cells of undetermined significance on cervical cytology. Gynecol Oncol 1997; 65: 314-318.
74. SOOFER SB, SIDAWY MK. Atypical glandular cells of undetermined significance. Cancer 2000; 90: 207-214.
75. EDDY GL, WOJTOWYCZ MA, PIRAINO PS, MAZUR MT. Papanicolaou smears by the Bethesda system in endometrial malignancy. Obstet Gynecol 1997; 90: 999-1003.
76. VEUOVICH DS, STOLER MH, ANDERSEN WA, COVELL JL, RICE LW. Atypical glandular cells of undetermined significance. Am J Obstet Gynecol 1998; 179: 382-390.
77. CHIENG DC, ELGERT P, COHEN JM, CANGIARELLA JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer 2001; 93: 1-7.
78. LAVERTY CR, FARNSWORTH A, THRLOE J, BOWDITCH R. The reliability of a cytological prediction of cervical adenocarcinoma in situ. Aust NZJ Obstet Gyneacol 1988; 28: 307-312.
79. LEE KR, MANNA EA, ST JOHN T. Atypical endocervical glandular cells: accuracy of ocytologic diagnosis. Diagn Cytopathol 1995; 13: 202-208.
80. MITCHELL H, MEDLY G, GORDON I, GILES G. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix. Br J Cancer 1995; 71: 894-897.
81. KIM TJ, KIM HS, PARK CT, et al. Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears. Gynecol Oncol 1999; 73: 292-298.
82. LEE KR, MINTER LJ, GRANTER SR. Papanicolaou smear sensitivity for adenocarcinoma in situ of the cervix: a study of 34 cases. Am J Clin Pathol 1997; 107: 30-35.
83. KRANE JF, GRANTER SR. TRASK CE, HOGAN CL, LEE KR. Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases. Cancer 2001; 93: 8-15.
84. CULLIMORE JE, LUESLEY DM, ROLLASON TP, et al. A prospective study of conization of the cervix in the management of cervical intraepithelial glandular neoplasia (CIGN): a preliminary report. Br J Obstet Gynaecol 1992; 99: 314-318.
85. DENEHY TR, GREGORI CA, BREEN JL. Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Obstet Gynecol 1997; 90: 1-6.
86. WOLF JK, LEVENBACK C, MALPICA A, MORRIS M, BURKE T, MITCHELL MF. Adenocarcinoma in situ of the cervix. Obstet Gynecol 1996; 88: 82-86.
87. GEIER CS, WILSON M, CREASMAN W. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol 2001; 184: 64-69.
88. CHIN AB, BRISTOW RE, KORST LM, WALTS A, LAGASSE LD. The significance of atypical glandular cells on routine cervical cytologic testing in a community-based population. Am J Obstet Gynecol 2000; 182: 1278-1282.
89. OSTOR AG, DUNCAN A, QUIN M, ROME R. Adenocarcinoma in situ of the uterine cervix: an experience with 100 cases. Gynecol Oncol 2000; 79: 207-210.
90. WIDRICH T, KENNEDY AW, MYERS TM, HART WT, WIRTH S. Adenocarcinoma in situ of the uterine cervix. Gynecol Oncol 1996; 61: 304-308.
91. MUNTZ HG, BELL DA, LAGE JM, GOFF BA, FELDMAN S. RICE LW. Adenocarcinoma in situ of the uterine cervix. Obstet Gynecol 1992; 80: 935-939.
92. COX JT. ASCCP Practice Guidelines: management of glandular abnormalities in the cervical smear. J Lower Gen Tract Dis 1997; 1: 41-45.